Theratechnologies dévoile le plan et les caractéristiques initiales de l'essai PROMISE-US sur l'ibalizumab chez les personnes vivant avec le VIH ayant reçu de nombreux traitements et présentant une multirésistance aux médicaments
October 17, 2024 07:30 ET
|
Theratechnologies
MONTRÉAL, 17 oct. 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (« Theratechnologies » ou la « Société ») (TSX : TH) (NASDAQ : THTX), une entreprise biopharmaceutique axée sur la mise au...
Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
October 17, 2024 07:30 ET
|
Theratechnologies
MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and...
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
September 18, 2023 07:30 ET
|
ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
April 06, 2023 08:30 ET
|
ContraFect Corporation
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism of Action of CF-370 YONKERS, N.Y., April 06, 2023 ...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
April 03, 2023 08:30 ET
|
ContraFect Corporation
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions
March 31, 2021 07:00 ET
|
Provectus Biopharmaceuticals Inc.
46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...
Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR720 and Announces Plans to Advance Program into Proof-of-Concept Clinical Trial in Patients with NTM Pulmonary Disease
December 04, 2019 16:01 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Third Quarter 2019 Operating Results and Provides Pipeline Review
November 04, 2019 16:05 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 31, 2019 17:00 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...
Spero Therapeutics Announces First Quarter 2019 Operating Results and Provides Pipeline Review
May 09, 2019 16:10 ET
|
Spero Therapeutics, Inc.
CAMBRIDGE, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and...